Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137423 | 0.82 | KDM1A (0.46) | KDM1ARAD52HDAC9CYP1A2MEN1 | |
| SCHEMBL28901494 | 0.82 | KDM1A (0.46) | KDM1ARAD52HDAC9CYP1A2MEN1 | |
| SCHEMBL6929005 | 0.80 | KDM1A (0.51) | KDM1ACYP1A2MEN1KMT2ATP53 | |
| SCHEMBL10644129 | 0.78 | SIGMAR1 (0.51) | KDM1ACYP1A2MEN1KMT2ACYP2C19 | |
| SCHEMBL30192046 | 0.77 | SIGMAR1 (0.53) | KDM1ACYP1A2MEN1KMT2ACYP2C19 | |
| SCHEMBL9665166 | 0.75 | KDM5A (0.51) | ALDH1A1KDM1AHDAC9APEX1CYP1A2 | |
| SCHEMBL60004 | 0.74 | RAD52 (0.55) | ALDH1A1KDM1ARAD52HDAC9CYP1A2 | |
| SCHEMBL9583389 | 0.74 | KDM1A (0.53) | KDM1ACYP1A2MEN1KMT2ATP53 | |
| SCHEMBL22709565 | 0.74 | ALDH1A1 (0.40) | ALDH1A1HDAC9CYP1A2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11149959 | 0.73 | RAD52 (0.53) | ALDH1A1KDM1ARAD52HDAC9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376427-B1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| CN-101896455-B | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE INC | 2015-04-29 | — | — | CN | disclosed |
| CN-101896455-B | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE INC | 2015-04-29 | — | — | CN | disclosed |
| CN-101896455-B | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE INC | 2015-04-29 | — | — | CN | disclosed |
| CN-102245564-B | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE BIOPHARMA R & D IP LLC | 2015-04-01 | — | — | CN | disclosed |
| CN-102245564-B | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE BIOPHARMA R & D IP LLC | 2015-04-01 | — | — | CN | disclosed |
| US-8969370-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969367-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969370-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969367-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| CN-101896455-A | 3-Carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists | THERAVANCE INC | 2010-11-24 | — | — | CN | disclosed |
| EP-2231585-A2 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231585-A2 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010068649-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20100144881-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2009076408-A3 | 3 -CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009076408-A2 | 3 -CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076408-A2 | 3 -CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | ALDH1A1 601/4885KDM1A 1623/4885RAD52 4464/4885 |
| US-20100144881-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | OPRM1, OPRK1, OPRL1 | ALDH1A1 1569/4885KDM1A 1464/4885RAD52 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.